Trial Profile

A global phase III study assessing Sintilimab in first-line esophageal carcinoma patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sintilimab (Primary)
Indications Carcinoma; Oesophageal cancer
Focus Therapeutic Use
Sponsors Innovent Biologics

Most Recent Events

06 Apr 2020 New trial record
30 Mar 2020 According to an Innovent biologics media release, the initiation approval in the U.S. from the FDA has been obtained. The company expects to enroll the first patient in the first half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com